alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 48 studies by Winblad B with an author at Karolinska Institutet (SE) (page 1 of 2) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 48 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 77 out of 100. The Lancet. Neurology 2005-11-01

Leisure-time physical activity at midlife at least twice a week was associated with a reduced risk of dementia and AD (odds ratio [OR] 0.48 [95% CI 0.25-0.91] and 0.38 [0.17-0.85], respectively), even after adjustments for age, sex, education, follow-up time, locomotor disorders, APOE genotype, vascular disorders, smoking, and alcohol drinking. 2 key findings →

Participants: 1,449 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Neurology 2013-04-17

This study is based on 2 cross-sectional surveys of people aged 75 years or over conducted in central Stockholm: the Kungsholmen Project (KP) (1987-1989, n = 1,700) and the Swedish National study on Aging and Care in Kungsholmen (SNAC-K) (2001-2004, n = 1,575). 4 key findings →

Design: cross-sectional Participants: 1,700 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

✓ Peer-reviewed alzhub usefulness score 73 out of 100. The Lancet. Neurology 2007-06-01

Of 1018 study patients enrolled, 508 were randomly assigned to rivastigmine and 510 to placebo; 17.3% of patients on rivastigmine and 21.4% on placebo progressed to AD (hazard ratio 0.85 [95% CI 0.64-1.12]; p=0.225). 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Kidney Function, Alzheimer Disease Blood Biomarkers, and Dementia Risk in Community-Dwelling Older Adults

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Neurology 2025-12-03

At baseline, 2,279 dementia-free participants with available blood samples were included (median age 72 (interquartile range, 61-81) years; 62% female). 4 key findings →

Design: cohort Participants: 2,279 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

An active and socially integrated lifestyle in late life might protect against dementia

✓ Peer-reviewed alzhub usefulness score 65 out of 100. The Lancet. Neurology 2004-06-01

The recent availability of longitudinal data on the possible association of different lifestyles with dementia and Alzheimer's disease (AD) allow some preliminary conclusions on this topic. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Patterns of chronic multimorbidity in the elderly population

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Journal of the American Geriatrics Society 2009-02-01

In persons with multimorbidity, there exists co-occurrence of diseases beyond chance, which clinicians need to take into account in their daily practice. 2 key findings →

Design: prospective cohort Participants: 1,099 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study

✓ Peer-reviewed alzhub usefulness score 63 out of 100. PharmacoEconomics 2024-11-01

Mean annual costs for individuals with clinically diagnosed AD were SEK 99,906, SEK 290,972, SEK 479,524, and SEK 795,617 in mild cognitive impairment (MCI), mild, moderate, and severe AD. 1 key finding →

Design: cohort Participants: 95,853 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Long-term metformin usage and cognitive function among older adults with diabetes

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Journal of Alzheimer's disease : JAD 2014-01-01

Evidence strongly supports the important role of insulin resistance in cognitive decline and dementia and suggests that insulin sensitizers may protect against cognitive decline in diabetic and pre-diabetic individuals. 5 key findings →

Design: cross-sectional Participants: 204 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Influence of social network on occurrence of dementia: a community-based longitudinal study

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Lancet (London, England) 2000-04-01

Those individuals living alone, and those without any close social ties, both had an adjusted relative risk for developing dementia of 1.5 (95% CI 1.0-2.1 and 1.0-2.4, respectively). 2 key findings →

Participants: 176 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The age-dependent relation of blood pressure to cognitive function and dementia

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The Lancet. Neurology 2005-08-01

The relation of blood pressure with cognitive function and dementia has, in recent years, received much attention from epidemiological research. 2 key findings →

Design: cross-sectional Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Diet Quality and Dementia Risk in Older Adults With Alzheimer Pathology

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA Network Open 2026-06-01

Over a mean follow-up of 8.4 years (range, Conclusions and relevance This cohort study of older adults found that adherence to a dietary pattern with lower inflammatory potential was associated with lower dementia risk among individuals with AD pathology and broader neurobiological risk. 3 key findings →

Design: cohort Participants: 1,865 Evidence: early

Full summary, score breakdown and related studies → Original source Free full text

Vitamin B(12) and folate in relation to the development of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2001-05-01

A population-based longitudinal study in Sweden, the Kungsholmen Project A random sample of 370 nondemented persons, aged 75 years and older and not treated with B(12) and folate, was followed for 3 years to detect incident AD cases. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2010-08-25

Elderly patients with diabetes develop more extensive vascular pathology, which alone or together with AD-type pathology (particularly in APOE ε4 carriers) results in increased dementia risk. 2 key findings →

Participants: 553 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Journal of cellular and molecular medicine 2008-02-08

The risk of dementia and Alzheimer's disease (AD) probably results from an interaction between genetic and environmental factors. 3 key findings →

Participants: 1,449 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project

✓ Peer-reviewed alzhub usefulness score 58 out of 100. American journal of epidemiology 2002-06-01

Recent findings suggest that a rich social network may decrease the risk of developing dementia. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Anaemia increases the risk of dementia in cognitively intact elderly

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurobiology of aging 2006-02-01

Although cross-sectional studies found an association between anaemia and dementia, longitudinal studies provided contradictory results. 4 key findings →

Design: cross-sectional Participants: 1,139 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Accelerated progression from mild cognitive impairment to dementia in people with diabetes

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Diabetes 2010-08-16

Diabetes and pre-diabetes substantially accelerate the progression from MCI to dementia, and anticipate dementia occurrence by more than 3 years in people with MCI. 3 key findings →

Participants: 302 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Archives of neurology 2004-12-01

Family history of dementia was associated with an increased risk of dementia and AD in this very old population, but only among APOE epsilon4 carriers. 5 key findings →

Design: cohort study Participants: 907 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed